The firm also offered updates on its autoimmune disease, newborn screening, and other specialty diagnostics businesses from the sidelines of the conference.

The issue of developing pediatric reference intervals for common laboratory tests has been one of the organization's priorities.

The ELISA-based CIZ1B Biomarker Blood Test for Lung Cancer is designed to detect the lung cancer-produced biomarker CIZ1B. It was developed by UK-based Cizzle Biotechnology, which licensed it in the ...

Genprex plans to potentially integrate TROP2 expression for patient selection in NSCLC clinical studies, while Roche will validate assays using its TROP2 antibody.

Last week, readers were most interested in a story about a staffing shortage at labs that run liquid biopsy tests as demand for the tests skyrocket.

Executives disclosed new directions in neurodegenerative disease testing and low-volume sample collection for high-volume testing.

The Chicago-based company is developing a POC field-effect transistor (FET)-based analyzer that it plans initially to target to the fertility testing space.

The Helsinki-based company said it will use the funds to support further development of its AI-based digital pathology platform.

HHS OIG issued five recommendations, including refunding the federal government $18.5 million, as well as additional refunds for other potential overpayments.

Staffing is an issue for the clinical lab industry writ large, but rapid growth in demand and quickly changing technology has made liquid biopsies a particularly tricky area.

NEW YORK – Siemens Healthineers on Friday raised its earnings expectations for fiscal 2026 in light of tariff refunds but lowered its overall revenue outlook due in part to declining revenue in the ...

This story has been updated to include comments from Labcorp's Q2 2026 earnings call. NEW YORK – Laboratory Corporation of America reported Thursday morning that its second-quarter revenue jumped 6 ...